CureVac NV
CVAC5.425USD
+0.015+0.28%
Market hours （ET）Quotes delayed by 15 min
1.22BMarket Cap
6.76P/E TTM
More Details of CureVac NV Company
CureVac NV, formerly CureVac AG, is a Germany-based clinical-stage biopharmaceutical company. The Company develops transformative medicines based on messenger ribonucleic acid, or mRNA. The Company's mRNAs are designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Its technology platform optimizes mRNA constructs that encode functional proteins which either induce a desired immune response or replace defective or missing proteins using the cell’s intrinsic translation machinery. The Company's product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and molecular therapy. In prophylactic vaccines, the Company is advancing its second-generation mRNA backbone against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and a range of infectious diseases, including seasonal influenza, in collaboration with GSK(Glaxo Smith Kline).
Company Info
Ticker SymbolCVAC
Company nameCureVac NV
IPO dateAug 14, 2020
CEODr. Alexander Zehnder, M.D.
Number of employees825
Security typeOrdinary Share
Fiscal year-endAug 14
AddressFriedrich-Miescher-Str. 15
CityTUEBINGEN
Stock exchangeNASDAQ Global Market Consolidated
CountryGermany
Postal code72076
Phone49707198830
Websitehttps://www.curevac.com/
Ticker SymbolCVAC
IPO dateAug 14, 2020
CEODr. Alexander Zehnder, M.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Baron Jean Stephenne
Mr. Baron Jean Stephenne
Independent Chairman of Supervisory Board
Independent Chairman of Supervisory Board
40.49K
+141.65%
Dr. Mathias Hothum, Ph.D.
Dr. Mathias Hothum, Ph.D.
Member of the Supervisory Board
Member of the Supervisory Board
29.31K
+170.24%
Mr. Craig A. Tooman
Mr. Craig A. Tooman
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
27.79K
+187.92%
Mr. Michael Brosnan
Mr. Michael Brosnan
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
19.75K
+371.79%
Mr. Axel-Sven Malkomes
Mr. Axel-Sven Malkomes
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Klaus Schollmeier, Ph.D.
Dr. Klaus Schollmeier, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Dr. Malte Greune, Ph.D.
Dr. Malte Greune, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
--
--
Dr. Debra Barker, M.D.
Dr. Debra Barker, M.D.
Member of the Supervisory Board
Member of the Supervisory Board
--
--
Dr. Alexander Zehnder, M.D.
Dr. Alexander Zehnder, M.D.
Chief Executive Officer, Member of the Management Board
Chief Executive Officer, Member of the Management Board
--
--
Dr. Myriam Mendila, M.D.
Dr. Myriam Mendila, M.D.
Chief Scientific Officer, Member of the Management Board
Chief Scientific Officer, Member of the Management Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Baron Jean Stephenne
Mr. Baron Jean Stephenne
Independent Chairman of Supervisory Board
Independent Chairman of Supervisory Board
40.49K
+141.65%
Dr. Mathias Hothum, Ph.D.
Dr. Mathias Hothum, Ph.D.
Member of the Supervisory Board
Member of the Supervisory Board
29.31K
+170.24%
Mr. Craig A. Tooman
Mr. Craig A. Tooman
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
27.79K
+187.92%
Mr. Michael Brosnan
Mr. Michael Brosnan
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
19.75K
+371.79%
Mr. Axel-Sven Malkomes
Mr. Axel-Sven Malkomes
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Klaus Schollmeier, Ph.D.
Dr. Klaus Schollmeier, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Revenue Breakdown
Currency: EURUpdated: Sun, Jul 6
Currency: EURUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
No Data
By RegionEUR
Name
Revenue
Proportion
Switzerland
586.00K
65.62%
Belgium (Country)
306.00K
34.27%
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, Jul 23
Updated: Wed, Jul 23
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
DH Capital GmbH & Co. KG
31.17%
KfW
13.27%
Glaxo Group, Ltd.
7.37%
DH-LT-Investments GmbH
3.89%
Zweite DH Verwaltungs GmbH
1.51%
Other
42.80%
Shareholders
Shareholders
Proportion
DH Capital GmbH & Co. KG
31.17%
KfW
13.27%
Glaxo Group, Ltd.
7.37%
DH-LT-Investments GmbH
3.89%
Zweite DH Verwaltungs GmbH
1.51%
Other
42.80%
Shareholder Types
Shareholders
Proportion
Corporation
36.61%
Government Agency
13.27%
Holding Company
7.37%
Investment Advisor
1.31%
Hedge Fund
0.93%
Investment Advisor/Hedge Fund
0.89%
Foundation
0.70%
Bank and Trust
0.41%
Research Firm
0.30%
Other
38.23%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
248
139.54M
61.97%
-14.77M
2025Q1
256
140.77M
62.52%
-15.67M
2024Q4
257
142.22M
63.40%
-15.15M
2024Q3
264
144.04M
64.21%
-15.50M
2024Q2
284
147.06M
65.56%
-13.88M
2024Q1
303
150.44M
67.06%
-10.89M
2023Q4
317
154.94M
69.64%
-16.33M
2023Q3
339
166.99M
75.03%
-5.02M
2023Q2
359
168.77M
75.83%
-4.22M
2023Q1
383
169.76M
76.27%
+21.54M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
DH Capital GmbH & Co. KG
70.18M
31.17%
--
--
Jun 12, 2025
KfW
29.87M
13.27%
--
--
Mar 15, 2025
Glaxo Group, Ltd.
16.59M
7.37%
--
--
Mar 15, 2025
DH-LT-Investments GmbH
8.75M
3.89%
--
--
Jun 12, 2025
Zweite DH Verwaltungs GmbH
3.40M
1.51%
--
--
Jun 12, 2025
Millennium Management LLC
1.82M
0.81%
+169.95K
+10.32%
Mar 31, 2025
Bill & Melinda Gates Foundation
1.57M
0.7%
-28.77K
-1.80%
Sep 30, 2024
BlackRock Institutional Trust Company, N.A.
598.13K
0.27%
-7.56K
-1.25%
Mar 31, 2025
UBS Switzerland AG
497.53K
0.22%
+424.90K
+585.03%
Mar 31, 2025
BlackRock Advisors (UK) Limited
347.00K
0.15%
+3.49K
+1.02%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Virtus LifeSci Biotech Clinical Trials ETF
0.87%
Global X Genomics & Biotechnology ETF
0.65%
WisdomTree BioRevolution Fund
0.56%
ProShares Ultra Nasdaq Biotechnology
0.14%
Invesco Nasdaq Biotechnology ETF
0.14%
iShares Biotechnology ETF
0.05%
iShares MSCI Europe Small-Cap ETF
0.04%
iShares MSCI EAFE Small-Cap ETF
0.02%
Xtrackers MSCI Eurozone Hedged Eqty ETF
0.01%
Fidelity Nasdaq Composite Index ETF
0.01%
View more
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.87%
Global X Genomics & Biotechnology ETF
Proportion0.65%
WisdomTree BioRevolution Fund
Proportion0.56%
ProShares Ultra Nasdaq Biotechnology
Proportion0.14%
Invesco Nasdaq Biotechnology ETF
Proportion0.14%
iShares Biotechnology ETF
Proportion0.05%
iShares MSCI Europe Small-Cap ETF
Proportion0.04%
iShares MSCI EAFE Small-Cap ETF
Proportion0.02%
Xtrackers MSCI Eurozone Hedged Eqty ETF
Proportion0.01%
Fidelity Nasdaq Composite Index ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
